BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19831557)

  • 1. Clinical review: treatment of vitreoretinal lymphoma.
    Pe'er J; Hochberg FH; Foster CS
    Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma.
    Rajagopal R; Harbour JW
    Retina; 2011 Mar; 31(3):435-40. PubMed ID: 21336066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
    Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
    JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
    Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
    Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for intraocular lymphoma.
    Itty S; Pulido JS
    Retina; 2009 Feb; 29(2):129-32. PubMed ID: 19202422
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary intraocular lymphoma: A review.
    Choi JY; Kafkala C; Foster CS
    Semin Ophthalmol; 2006; 21(3):125-33. PubMed ID: 16912010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy.
    Itty S; Olson JH; O'Connell DJ; Pulido JS
    Retina; 2009 Mar; 29(3):415-6. PubMed ID: 19174721
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intravitreal chemotherapy for intraocular lymphoma].
    Helbig H; Cerny T; de Smet MD
    Ophthalmologe; 2003 Feb; 100(2):145-9. PubMed ID: 12589460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular lymphoma: report of three cases and review of the literature.
    Trudeau M; Shepherd FA; Blackstein ME; Gospodarowicz M; Fitzpatrick P; Moffatt KP
    Am J Clin Oncol; 1988 Apr; 11(2):126-30. PubMed ID: 3282423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
    Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
    Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate.
    de Smet MD
    Bull Soc Belge Ophtalmol; 2001; (279):91-5. PubMed ID: 11344720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
    Kvopka M; Lake SR; Smith JR
    Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
    Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
    Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
    Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
    Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
    Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
    Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
    Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular use of rituximab.
    Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
    Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma.
    Velez G; Boldt HC; Whitcup SM; Nussenblatt RB; Robinson MR
    Ophthalmic Surg Lasers; 2002; 33(4):329-33. PubMed ID: 12134997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostics and treatment of primary vitreoretinal lymphoma].
    Stübiger N; Kakkassery V; Gundlach E; Winterhalter S; Pleyer U
    Ophthalmologe; 2015 Mar; 112(3):223-30. PubMed ID: 25698590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.